34results about How to "% efficacy" patented technology

Described is a method for at least in part decreasing the production of an aberrant protein in a cell, the cell comprising pre-mRNA comprising exons coding for the protein, by inducing so-called exon skipping in the cell. Exon-skipping results in mature mRNA that does not contain the skipped exon, which leads to an altered product of the exon codes for amino acids. Exon skipping is performed by providing a cell with an agent capable of specifically inhibiting an exon inclusion signal, for instance, an exon recognition sequence, of the exon. The exon inclusion signal can be interfered with by a nucleic acid comprising complementarity to a part of the exon. The nucleic acid, which is also herewith provided, can be used for the preparation of a medicament, for instance, for the treatment of an inherited disease.

A nutritional booster composition suitable for the treatment of pressure ulcers, comprising proteins, carbohydrates and fats and, in a daily unit dose: 3-15 g of arginine or equivalents thereof, 180-840 mg of ascorbic acid equivalents, 50-400 mg of α-tocopherol equivalents, and 8-40 mg of flavonoids.

The invention discloses a compound gingko health product solid preparation which is prepared by mixing ginkgo leaf extract, salvia miltiorrhiza bunge, American ginseng, seabuckthorn flavone and gelatin or an enteric substrate. The compound gingko health product solid preparation comprises the following effective components in parts by weight: 1-60 parts of ginkgo leaf extract, 1-60 parts of salvia miltiorrhiza bunge, 1-30 parts of American ginseng and 0.5-20 parts of seabuckthorn flavone. The gingko, the salvia miltiorrhiza bunge, the American ginseng and the seabuckthorn flavone are comprehensively mixed to achieve the effects of convenient use and comprehensive nourishing. The health product of the compound gingko health product solid preparation has values as both food and medicine and can be used by a patient with a cerebral-vascular disease and a patient with higher blood fat and used for resisting cancer, resisting fatigue, resisting anoxia, resisting radiation, resisting aging, strengthening immunity, and the like by a healthy person. The compound gingko health product solid preparation mainly has two formulations of pills and soft capsules, is convenient for use, is beneficial to absorption and meets the requirement on health by wide consumers.

The present invention provides compositions and methods for delivering a nucleotide sequence to a cell using an alphavirus vector that is complexed with an enhancing antibody that specifically binds to the alphavirus vector. Venezuelan Equine Encephalitis vectors are preferred. The cell may be a cell in vitro or in vivo. Alternatively, the cell may be removed from a subject, administered the alphavirus vector ex vivo and then administered to a subject. Antigen-presenting cells are preferred, with dendritic cells being more preferred. Also provided are methods of producing an immune response in a subject, e.g., for producing an immune response against an antigen associated with a pathogen or for immunotherapy of cancer of tumors.

The use of inhibitors of glucosylceramide synthesis or agents capable of increasing the rate of neuronal glycolipid degradation in the treatment of glycolipid storage related disorders including mucopolysaccharidosis diseases.

The present invention relates to a novel recombinant adenovirus (RAdEs) vaccine against JEV infection; an effective and superior method of immunization to Japanese encephalitis virus (JEV) infection; also, a method of preparing the recombinant adenovirus (RAdEs) vaccine.

The present invention provides a formulation which contains a poorly water soluble pharmaceutically active compound at a concentration of 50 mg per 100 g formulation or above. The solubility is achieved by a mixture of solvents as described herein. Moreover the formulation as described herein may be used as a base formulation to generate a cream, an ointment, a spray, a foam or an oleogel.

The invention described herein is directed to copper-containing compounds for the treatment of toxin exposure (including pore-forming toxin exposure) in a subject in need thereof. The invention is further directed to methods of treating toxin exposure in a subject in need thereof.

Presented herein, in certain embodiments, are compositions comprising antibody binding agents that specifically bind to A. baumannii and inhibit and/or block A. baumannii infection, and uses thereof.

The present invention provides a new treatment for idiopathic hypohidrosis. In one embodiment, the said treatment comprises administering to a patient in need a pharmaceutically effective amount of a retinoid. Preferably, the retinoid is isotretinoin or acitretin.

Disclosed is a use of ethyl p-methoxycinnamate and derivatives thereof in preparing drugs, culture media, regulating agents or cosmetic and skin caring products for maintaining self-renewal and pluripotency of stem cells. The stem cells comprise adult stem cells, embryonic stem cells and induced pluripotent stem (iPS) cells. Also disclosed is a use of ethyl p-methoxycinnamate and the derivatives thereof in in-vitro amplification of stem cells and preparation of induced pluripotent stem (iPS) cells and a use of ethyl p-methoxycinnamate and the derivatives thereof in preparing drugs for treating cell deletion or injury diseases.